AptarGroup target raised to $174 on maintained Buy rating

On Thursday, BofA Securities updated its outlook on AptarGroup (NYSE:ATR), increasing the price target to $174 from $168, while keeping a Buy rating on the stock. The adjustment follows a recent assessment of the company's financial prospects.

The firm's analyst cited specific challenges within the Aerospace, Electronics and Communications (AEC) segment, which experienced negative Earnings Before Interest and Taxes (EBIT) of $24 million. The majority of these charges were associated with the CH-53K and Gulfstream programs. Additionally, $2 million of the negative EBIT was connected to the LEAP and 787 programs. These figures reflect the latest pre-announcement from the company.

Management's commentary highlighted the uncertainty in demand for these aerospace programs, with a cautious approach towards inventory buildup in the channel. The ongoing strike at Boeing (NYSE:NYSE:BA), which is not currently rated by BofA Securities, was identified as a significant event to monitor, although the present revisions in estimates appear to be specific to AptarGroup and not reflective of wider supply chain issues.

The revised price target and maintained Buy rating indicate BofA Securities' continued confidence in AptarGroup's stock despite the recent pre-announcement and the specific setbacks in the AEC segment. The firm's analysis suggests that the issues faced are isolated and do not point to broader industry supply chain problems at this time.

"In other recent news, AptarGroup, Inc. has witnessed significant developments. The company's N-Sorb nitrosamine mitigation solution was accepted into the U.S. Food & Drug Administration's Emerging Technology Program. This innovative technology, which addresses concerns about N-nitrosamine impurities in pharmaceuticals, aligns with the FDA's updated guidance on mitigating nitrosamine risks.

Moreover, Aptar reported robust growth in its second quarter of 2024, primarily driven by a 7% increase in core sales in its pharma segment. The company also reported a 3% increase in overall core sales and a 12% rise in adjusted earnings per share (EPS). However, sales in the beauty segment experienced a decline, largely due to weaker sales in Europe.

Looking ahead, Aptar anticipates growth in the pharma segment to continue into the third quarter, with predicted adjusted EPS between $1.38 and $1.46 per share. Despite the decrease in beauty segment sales, the company maintains a solid balance sheet, a leverage ratio of approximately 1.3, and is open to bolt-on acquisitions.

InvestingPro Insights

To complement BofA Securities' analysis of AptarGroup (NYSE:ATR), recent data from InvestingPro offers additional context. Despite the challenges in the AEC segment, ATR's financial health appears robust. The company boasts a market capitalization of $10.62 billion and has demonstrated strong revenue growth of 4.96% over the last twelve months as of Q2 2024, with revenues reaching $3.56 billion.

InvestingPro Tips highlight ATR's commitment to shareholder returns, having raised its dividend for 31 consecutive years and maintained payments for 32 years. This consistency is particularly noteworthy given the recent headwinds in the aerospace sector. The company's dividend yield stands at 1.13%, with an impressive dividend growth of 18.42% in the last twelve months.

While BofA Securities maintains a Buy rating, investors should note that ATR is trading near its 52-week high, with the stock price at 99.25% of its peak. This aligns with the InvestingPro Tip suggesting the stock may be in overbought territory based on its RSI.

For those seeking a more comprehensive analysis, InvestingPro offers 12 additional tips on ATR, providing a deeper dive into the company's financial position and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.